Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
L. Ezcurdia(Argentine Antarctic Institute), A.M. Alvarez, G Uranga, G Temperley, J. Polera, C. Blajman, G Pasccón, Eduardo Triguboff, Alberto Luchina, E. Mickiewicz(University of Chicago), M. Rondinón, Hebe Margot Fasce(Instituto Oncológico de Córdoba), Luis Fein(National Cancer Center), Eduardo Cazap(Facultad Latinoamericana de Ciencias Argentina), Gonzalo Rubio, Federico Cóppola(Hospital Alemán), S Jovtis, Carlos A. Martínez(Pontificia Universidad Católica de Valparaíso), S. Breier, Daniel Lewi, Pedro M. Politi
PubMed
October 1, 1997
Cited by 14
Related Papers
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
|Journal of Clinical Oncology|2007|483
Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial
|Journal of Clinical Oncology|2000|318